Add Yahoo as a preferred source to see more of our stories on Google. Texans should turn clocks on their non-smart devices forward one hour on Sunday, March 8. (Sina Schuldt/Picture Alliance via Getty ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. 10 stocks we like better than Eli Lilly ...

Novo Nordisk shares look cheap, but execution and management changes weigh on investor confidence. Eli Lilly’s stronger GLP-1 growth and consistency support its premium versus Novo’s conditional value ...

And what's remarkable is that Lilly’s biopharma competitors don't own the size of a franchise in obesity drugs as compared to Lilly or Novo. Companies like Pfizer (PFE) have made headlines recently as ...

Genentech on Thursday shared topline results from the Phase 2 ZUPREME-1 trial evaluating petrelintide versus placebo in 493 obese participants (mean BMI of 37 kg/m²). In 2025, Genentech and Roche ...

Eli Lilly has launched Employer Connect, a platform that offers employers a direct route to offer Zepbound coverage to workers at a list price of $449 per month, bypassing traditional pharmacy ...

Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients. The "Employer Connect" platform gives employers more ...

Novo Nordisk shares sank after the Danish drugmaker suffered a setback in its battle with Eli Lilly to dominate the market for weight-loss drugs.

Eli Lilly (LLY) shares turned lower in the premarket on Tuesday after its rival Novo Nordisk (NVO) announced plans to cut the list prices of its GLP-1 medications, Wegovy, Ozempic, and Rybelsus, in ...